Heraeus expands its platinum-based HPAPI capacity
Company's multimillion euro investment will enable it to meet growing market demands from clients providing cancer treatments.
Heraeus Pharmaceutical Ingredients, a business line of Heraeus Precious Metals, has expanded its capacity for platinum-based highly potent active pharmaceutical ingredients (HPAPIs) with an additional production line built at the company’s headquarters in Hanau, Germany.
Heraeus is the leading market supplier for Platinum-based HPAPIs, which are a key component used in cancer chemotherapy. As cancer cases rise across the globe, Heraeus has increased its production capabilities to ensure it leads the drive for much-needed capacity to meet the long-term global market demand.
The technical set-up of the new production line is now complete and commercial production is scheduled to begin in 2020 upon completion of the validation process.
Dr Marcus Hannakam, Head of Heraeus’ Pharmaceutical Ingredients Business Line said: “This multimillion euro investment in additional capacity underlines our commitment to lead in this field and help our customers in the vital job of providing the drugs to treat cancer patients across the globe.
“We have a proud tradition in high-quality precious metal technologies and a continued focus on fostering long-term partnerships with our customers who work on therapies to fight cancer.
“With the technical set-up of our new production line now complete, we are primed and ready to meet the growing market demands from our clients for platinum-based HPAPIs and lifesaving treatments for cancer patients.”
Platinum-based HPAPIs are used in chemotherapy treatments to combat a range of cancers, including lung, colorectal, ovarian and testicular cancer. The need for these particular HPAPIs in cancer treatment has been rocketing due to demographic changes leading to more cancer cases, emerging countries gaining access to chemotherapy and usage of platinum-based HPAPIs in combination therapy.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance